

## Renal Cancer

**CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.** *First Author: Arnaud Méjean*

**Conclusions:** Sunitinib alone is not inferior to CN followed by sunitinib in synchronous mRCC both in intermediate and poor MSKCC risk groups. CN should not be anymore the standard of care when medical treatment is required. Clinical trial information: [NCT00930033](https://clinicaltrials.gov/ct2/show/study/NCT00930033)

[J Clin Oncol 36, 2018 \(suppl; abstr LBA3\)](#)

[SEE ALSO PUBLICATION IN THE NEJM](#)

EDITORIAL NEJM - R.J. Motzer & P. Russo: [Cytoreductive Nephrectomy — Patient Selection Is Key](#)